Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of APIs, finished formulations, R&D, clinical research with presence in Latin America, Africa, USA and other nations.
Financial Results:
Caplin Point Laboratories Ltd reported Revenues for Q3FY25 of ₹493.00 Crores up from ₹436.00 Crore year on year, a rise of 13.07%.
Total Expenses for Q3FY25 of ₹347.00 Crores up from ₹307.00 Crores year on year, a rise of 13.03%.
Consolidated Net Profit of ₹140.00 Crores up 16.67% from ₹120.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹18.28, up 18.47% from ₹15.43 in the same quarter of the previous year.
![](data:image/svg+xml;charset=utf-8,<svg height="781px" width="640px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
